Amarin Claims ‘Little Impact’ From Teva’s US Vascepa Generic
Originator Aware Of Potential Fifth Launch From Zydus Cadila
“They have prescriptions just in the hundreds per week, which is in a market of 100,000 or so prescriptions a week,” Amarin has said of Teva’s Vascepa generic, the fourth to reach the US market.
You may also be interested in...
Zydus Looks To NASH Trials In Turkey, gVascepa Launch In The US
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter
Hikma Slams Amarin In Vascepa Antitrust Suit For ‘Locking Up API Supply’
Amarin is facing up to another antitrust lawsuit over its alleged control of API supply for its Vascepa brand.
Juno Looks To Shore Up Canada Supply Chains With Omega Deal
Quickfire M&A has been unveiled in Canada, with Juno Pharmaceuticals taking control of the former Nichi-Iko affiliate Omega Laboratories.